Abstract
median OS was 35 months (95% CI: 29,3-40,6). There were significant differents in PFS between patients who underwent surgery of metastases versus non-operated (p = 0.001) by Log-Rank test. Conclusions: Neoadyuvant RCT is feasible approach for metastatic rectal cancer, offering good outcomes in-field tumor control, survival and low toxicity profile. Further investigation is warranted in order to define their integration into the multimodality treatment in this patient population.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have